ADENOID CYSTIC CARCINOMA
Clinical trials for ADENOID CYSTIC CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ADENOID CYSTIC CARCINOMA trials appear
Sign up with your email to follow new studies for ADENOID CYSTIC CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug targets Notch-Activated cancer before surgery
Disease control CompletedThis phase 1 trial tested the drug AL101 in 13 people with a rare salivary gland cancer called adenoid cystic carcinoma that has a specific genetic change (notch activation). Participants received AL101 before their standard surgery to see if it is safe and might help control the…
Matched conditions: ADENOID CYSTIC CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Immune cell combo shows promise in tough head and neck cancers
Disease control CompletedThis early-phase trial tested a new approach for people with advanced head and neck cancer that has come back or spread. It combined specially trained natural killer (NK) immune cells with drugs that help the immune system attack cancer. The study enrolled 11 participants to chec…
Matched conditions: ADENOID CYSTIC CARCINOMA
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New cancer drug shows promise in early trial
Disease control CompletedThis phase 1 study tested an experimental drug called LY3039478 in 247 people with advanced or metastatic cancer, including lymphoma. The main goal was to find a safe dose and see how the drug affects the body. Researchers also looked for signs that the drug might shrink tumors.
Matched conditions: ADENOID CYSTIC CARCINOMA
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Immunotherapy combo shows promise for rare salivary cancer
Disease control CompletedThis study tested two immunotherapy drugs, nivolumab and ipilimumab, in 64 people with recurrent or metastatic salivary gland cancer that could not be removed by surgery or treated with radiation. The goal was to see how well the combination shrank tumors and what side effects oc…
Matched conditions: ADENOID CYSTIC CARCINOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Cancer drug shows promise for rare salivary gland tumor
Disease control CompletedThis phase II trial tested the oral drug regorafenib in 38 patients with progressive, recurrent, or metastatic adenoid cystic carcinoma, a rare cancer of the salivary glands. Regorafenib works by blocking signals that help cancer cells grow and by cutting off blood supply to tumo…
Matched conditions: ADENOID CYSTIC CARCINOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 26, 2026 15:32 UTC